Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Lenalidomide Maintenance in DLBCL
NCT06503263Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Jul 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL). Started Aug 2024; status: recruiting.
02
Drugs
zanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06503263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503263.